APA (7th ed.) Citation

JJ, L., MR, P., GR, B., E, H., B, C., SV, U., . . . PA, M. (2023). The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: A phase 1 trial. Nature medicine, 29(11), 2814. https://doi.org/10.1038/s41591-023-02593-0

Chicago Style (17th ed.) Citation

JJ, Luke, et al. "The PD-1- and LAG-3-targeting Bispecific Molecule Tebotelimab in Solid Tumors and Hematologic Cancers: A Phase 1 Trial." Nature Medicine 29, no. 11 (2023): 2814. https://doi.org/10.1038/s41591-023-02593-0.

MLA (9th ed.) Citation

JJ, Luke, et al. "The PD-1- and LAG-3-targeting Bispecific Molecule Tebotelimab in Solid Tumors and Hematologic Cancers: A Phase 1 Trial." Nature Medicine, vol. 29, no. 11, 2023, p. 2814, https://doi.org/10.1038/s41591-023-02593-0.